Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.

Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fucà G, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, Lo Russo G.

Lung Cancer. 2019 Jun;132:72-78. doi: 10.1016/j.lungcan.2019.04.008. Epub 2019 Apr 8.

PMID:
31097097
2.

Avelumab in gastric cancer.

Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini N, Sobhani N.

Immunotherapy. 2019 Jun;11(9):759-768. doi: 10.2217/imt-2019-0011. Epub 2019 May 6.

PMID:
31060469
3.

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D.

ESMO Open. 2019 Feb 27;4(1):e000457. doi: 10.1136/esmoopen-2018-000457. eCollection 2019.

4.

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.

Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC.

Cancer Treat Rev. 2019 May;75:39-51. doi: 10.1016/j.ctrv.2019.03.004. Epub 2019 Mar 28. Review.

PMID:
30954906
5.

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.

Vernieri C, Signorelli D, Galli G, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Rizzo AM, Corsetto PA, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC.

Clin Lung Cancer. 2019 May;20(3):e413-e417. doi: 10.1016/j.cllc.2018.12.011. Epub 2018 Dec 19.

PMID:
30617039
6.

Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Vitali M, Ganzinelli M, Lanti C, Molino G, Stangoni F, Zilembo N, de Braud F, Garassino MC, Signorelli D.

Target Oncol. 2018 Dec;13(6):795-800. doi: 10.1007/s11523-018-0599-5.

PMID:
30306460
7.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

PMID:
30206165
8.

Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.

Moro M, Caiola E, Ganzinelli M, Zulato E, Rulli E, Marabese M, Centonze G, Busico A, Pastorino U, de Braud FG, Vernieri C, Simbolo M, Bria E, Scarpa A, Indraccolo S, Broggini M, Sozzi G, Garassino MC.

J Thorac Oncol. 2018 Nov;13(11):1692-1704. doi: 10.1016/j.jtho.2018.07.102. Epub 2018 Aug 24.

9.

RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.

Tessari A, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, Foray C, Fabbri A, Embrione V, Ganzinelli M, Capece M, Campbell MJ, Broggini M, La Perle K, Farina G, Cole S, Marabese M, Hernandez M, Amann JM, Pruneri G, Carbone DP, Garassino MC, Croce CM, Palmieri D, Coppola V.

Oncogene. 2018 Dec;37(50):6463-6476. doi: 10.1038/s41388-018-0424-8. Epub 2018 Aug 3.

PMID:
30076413
10.

RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.

Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G, Petrini I, Palmieri G, Berardi R, Zucali P, Ganzinelli M, Marabese M, Broggini M, Marino M, Trama A, Rulli E, Hollander L, Pruneri G, Torri V, Garassino MC.

Clin Lung Cancer. 2018 Sep;19(5):e811-e814. doi: 10.1016/j.cllc.2018.06.005. Epub 2018 Jul 3.

PMID:
30033090
11.

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.

Guffanti F, Fratelli M, Ganzinelli M, Bolis M, Ricci F, Bizzaro F, Chilà R, Sina FP, Fruscio R, Lupia M, Cavallaro U, Cappelletti MR, Generali D, Giavazzi R, Damia G.

Oncotarget. 2018 May 15;9(37):24707-24717. doi: 10.18632/oncotarget.25185. eCollection 2018 May 15.

12.

Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.

Galli G, Corrao G, Imbimbo M, Proto C, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, de Braud F, Garassino MC, Lo Russo G.

Lung Cancer. 2018 Jan;115:135-142. doi: 10.1016/j.lungcan.2017.12.002. Epub 2017 Dec 5. Review.

PMID:
29290256
13.

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.

Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC.

Oncotarget. 2017 Apr 26;8(35):59889-59900. doi: 10.18632/oncotarget.17431. eCollection 2017 Aug 29. Review.

14.

Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.

Proto C, Lo Russo G, Corrao G, Ganzinelli M, Facchinetti F, Minari R, Tiseo M, Garassino MC.

Tumori. 2017 Jul 31;103(4):325-337. doi: 10.5301/tj.5000663. Epub 2017 Jul 1. Review.

PMID:
28708233
15.

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, Lo Russo G.

Transl Lung Cancer Res. 2016 Dec;5(6):563-578. doi: 10.21037/tlcr.2016.10.16. Review.

16.

The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.

Rulli E, Guffanti F, Caiola E, Ganzinelli M, Damia G, Garassino MC, Piva S, Ceppi L, Broggini M, Marabese M.

Sci Rep. 2016 Dec 14;6:39217. doi: 10.1038/srep39217.

17.

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregni E, de Braud F, Garassino MC.

Tumour Biol. 2016 Oct;37(10):12991-13003. Epub 2016 Jul 27. Review.

PMID:
27460087
18.

DNA repair gene polymorphisms in non-small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.

Rulli E, Marabese M, Piva S, Bonomi L, Caiola E, Ganzinelli M.

Tumori. 2016 Aug 3;102(4):367-75. doi: 10.5301/tj.5000526. Epub 2016 Jul 7.

PMID:
27396427
19.

Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

Macerelli M, Ganzinelli M, Gouedard C, Broggini M, Garassino MC, Linardou H, Damia G, Wiesmüller L.

Cancer Treat Rev. 2016 Jul;48:8-19. doi: 10.1016/j.ctrv.2016.05.004. Epub 2016 May 24. Review.

PMID:
27262017
20.

Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer.

Gevorgyan A, Bregni G, Galli G, Ganzinelli M, Martinetti A, Lo Vullo S, Mariani L, Festinese F, Sottotetti E, de Braud F, Di Cosimo S.

Tumori. 2016 Aug 3;102(4):e11-4. doi: 10.5301/tj.5000515.

PMID:
27174629
21.

Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.

Lo Russo G, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, Proto C, Ganzinelli M, Gallucci R, Agustoni F, Fasola G, de Braud F, Garassino MC.

Curr Drug Targets. 2017;18(3):341-362. doi: 10.2174/1389450117666160502152331. Review.

PMID:
27138756
22.

G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.

Marabese M, Caiola E, Garassino MC, Rastelli G, Settanni G, Brugnara S, Broggini M, Ganzinelli M.

J Thorac Oncol. 2016 Jul;11(7):1170-5. doi: 10.1016/j.jtho.2016.03.013. Epub 2016 Apr 4.

23.

Treatment of lung large cell neuroendocrine carcinoma.

Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC.

Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4. Review.

PMID:
26943800
24.

Diagnosis and management of typical and atypical lung carcinoids.

Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC.

Crit Rev Oncol Hematol. 2016 Apr;100:167-76. doi: 10.1016/j.critrevonc.2016.02.009. Epub 2016 Feb 18. Review.

PMID:
26917456
25.

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.

de Oliveira SF, Ganzinelli M, Chilà R, Serino L, Maciel ME, Urban Cde A, de Lima RS, Cavalli IJ, Generali D, Broggini M, Damia G, Ribeiro EM.

PLoS One. 2016 Jan 11;11(1):e0145647. doi: 10.1371/journal.pone.0145647. eCollection 2016.

26.

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).

Ganzinelli M, Rulli E, Caiola E, Garassino MC, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Fabbri MA, Martelli O, Fagnani D, Locatelli MC, Bertolini A, Valmadre G, Pavese I, Calcagno A, Sarobba MG, Marabese M.

Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331.

27.

Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?

Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Lo Russo G.

Tumori. 2016 Jan-Feb;102(1):18-30. doi: 10.5301/tj.5000436. Epub 2015 Oct 14. Review.

PMID:
26481865
28.

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.

Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E.

Oncotarget. 2015 Oct 20;6(32):34014-22. doi: 10.18632/oncotarget.5607.

29.

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC; TAILOR trialists.

Ann Oncol. 2015 Oct;26(10):2079-84. doi: 10.1093/annonc/mdv318. Epub 2015 Jul 24.

PMID:
26209642
30.

Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.

Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R.

Cancer Res. 2014 Dec 1;74(23):6980-90. doi: 10.1158/0008-5472.CAN-14-0274. Epub 2014 Oct 10.

31.

Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin.

La Verde N, Piva S, Ganzinelli M, Farina G, Gherardi G, Girelli S, Bramati A, Del Re L, Damia G.

Future Oncol. 2013 Nov;9(11):1703-9. doi: 10.2217/fon.13.169.

PMID:
24156329
32.

Across the universe of K-RAS mutations in non-small-cell-lung cancer.

Piva S, Ganzinelli M, Garassino MC, Caiola E, Farina G, Broggini M, Marabese M.

Curr Pharm Des. 2014;20(24):3933-43. Review.

PMID:
24138715
33.

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists.

Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22.

PMID:
23883922
34.

Triple negative breast cancers have a reduced expression of DNA repair genes.

Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox SB, Broggini M, Bottini A, Zanoni V, Bazzola L, Foroni C, Generali D, Damia G.

PLoS One. 2013 Jun 25;8(6):e66243. doi: 10.1371/journal.pone.0066243. Print 2013.

35.

Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.

Sabatino MA, Geroni C, Ganzinelli M, Ceruti R, Broggini M.

Epigenetics. 2013 Jun;8(6):656-65. doi: 10.4161/epi.24916. Epub 2013 Jun 14.

36.

Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.

Garassino MC, Piva S, La Verde N, Spagnoletti I, Iorno V, Carbone C, Febbraro A, Bianchi A, Bramati A, Moretti A, Ganzinelli M, Marabese M, Gentili M, Torri V, Farina G.

PLoS One. 2013;8(4):e59981. doi: 10.1371/journal.pone.0059981. Epub 2013 Apr 5.

37.

Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.

Ricci F, Bernasconi S, Perego P, Ganzinelli M, Russo G, Bono F, Mangioni C, Fruscio R, Signorelli M, Broggini M, Damia G.

Cell Cycle. 2012 May 15;11(10):1966-76. doi: 10.4161/cc.20308. Epub 2012 May 15.

PMID:
22544328
38.

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.

Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison GP, Watson AJ, Caccuri AM, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero JC, Erba E, D'Incalci M.

Int J Cancer. 2012 Jul 1;131(1):59-69. doi: 10.1002/ijc.26340. Epub 2011 Aug 30.

39.

Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations.

Ganzinelli M, Mariani P, Cattaneo D, Fossati R, Fruscio R, Corso S, Ricci F, Broggini M, Damia G.

Eur J Cancer. 2011 May;47(7):1086-94. doi: 10.1016/j.ejca.2010.11.029. Epub 2011 Jan 7.

PMID:
21216588
40.

Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells.

Sabatino MA, Marabese M, Ganzinelli M, Caiola E, Geroni C, Broggini M.

Mol Cancer. 2010 Sep 24;9:259. doi: 10.1186/1476-4598-9-259.

41.

Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.

Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggini M, Damia G.

Clin Cancer Res. 2008 Aug 15;14(16):5131-41. doi: 10.1158/1078-0432.CCR-08-0304.

Supplemental Content

Loading ...
Support Center